

**EKF Diagnostics Holdings plc**  
("EKF", the "Company" or the "Group")

**Change of Adviser**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces Singer Capital Markets as sole broker to the Company. Singer Capital Markets also continues to act as Nominated Adviser.

**EKF Diagnostics Holdings plc**

Mike Salter, CEO / Marc Davies, CFO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)

Tel: +44 (0)29 2071 0570

**Singer Capital Markets (Nominated Adviser & Broker)**

Aubrey Powell / George Tzimas / Oliver Platts

Tel: +44 (0)20 7496 3000

**Walbrook PR Limited**

Paul McManus / Lianne Applegarth

Tel: +44 (0)20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

**About EKF Diagnostics Holdings plc ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))**

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

<b>Point-of-Care</b>	Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
<b>Central Laboratory</b>	Clinical chemistry, Small lab analysers, Centrifuges <i>Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin</i>
<b>Life Sciences</b>	Enzyme fermentation, Custom products and Bulk fermentation
<b>Contract Manufacturing</b>	Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
<b>Laboratory Testing</b>	Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPDZGGMLDNGFZG